141 related articles for article (PubMed ID: 29979895)
1. The efficiency-frontier approach for health economic evaluation versus cost-effectiveness thresholds and internal reference pricing: combining the best of both worlds?
Sandmann FG; Mostardt S; Lhachimi SK; Gerber-Grote A
Expert Rev Pharmacoecon Outcomes Res; 2018 Oct; 18(5):475-486. PubMed ID: 29979895
[TBL] [Abstract][Full Text] [Related]
2. The efficiency frontier approach to economic evaluation: will it help German policy making?
Brouwer WB; Rutten FF
Health Econ; 2010 Oct; 19(10):1128-31. PubMed ID: 20641141
[No Abstract] [Full Text] [Related]
3. Convergence of decision rules for value-based pricing of new innovative drugs.
Gandjour A
Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):209-13. PubMed ID: 25327543
[TBL] [Abstract][Full Text] [Related]
4. New decision-making processes for the pricing of health technologies in Japan: The FY 2016/2017 pilot phase for the introduction of economic evaluations.
Shiroiwa T; Fukuda T; Ikeda S; Takura T
Health Policy; 2017 Aug; 121(8):836-841. PubMed ID: 28687183
[TBL] [Abstract][Full Text] [Related]
5. The Probabilistic Efficiency Frontier: A Framework for Cost-Effectiveness Analysis in Germany Put into Practice for Hepatitis C Treatment Options.
Mühlbacher AC; Sadler A
Value Health; 2017 Feb; 20(2):266-272. PubMed ID: 28237207
[TBL] [Abstract][Full Text] [Related]
6. Cardiac resynchronization therapy (CRT) in heart failure--a model to assess the economic value of this new medical technology.
Banz K;
Value Health; 2005; 8(2):128-39. PubMed ID: 15804321
[TBL] [Abstract][Full Text] [Related]
7. Methods for determining cost-benefit ratios for pharmaceuticals in Germany.
von der Schulenburg J; Vauth C; Mittendorf T; Greiner W
Eur J Health Econ; 2007 Sep; 8 Suppl 1():S5-31. PubMed ID: 17582539
[TBL] [Abstract][Full Text] [Related]
8. Self-monitoring of blood glucose (SMBG) in patients with type 2 diabetes on oral anti-diabetes drugs: cost-effectiveness in France, Germany, Italy, and Spain.
Tunis SL; Willis WD; Foos V
Curr Med Res Opin; 2010 Jan; 26(1):163-75. PubMed ID: 19919377
[TBL] [Abstract][Full Text] [Related]
9. The efficiency frontier approach to economic evaluation of health-care interventions.
Caro JJ; Nord E; Siebert U; McGuire A; McGregor M; Henry D; de Pouvourville G; Atella V; Kolominsky-Rabas P
Health Econ; 2010 Oct; 19(10):1117-27. PubMed ID: 20575151
[TBL] [Abstract][Full Text] [Related]
10. Controversy Over Using Quality-Adjusted Life-Years In Cost-Effectiveness Analyses: A Systematic Literature Review.
Rand LZ; Kesselheim AS
Health Aff (Millwood); 2021 Sep; 40(9):1402-1410. PubMed ID: 34495724
[TBL] [Abstract][Full Text] [Related]
11. Are current ICER thresholds outdated? Valuing medicines in the era of personalized healthcare.
Carrera P; IJzerman MJ
Expert Rev Pharmacoecon Outcomes Res; 2016 Aug; 16(4):435-7. PubMed ID: 27118144
[No Abstract] [Full Text] [Related]
12. Cost-effectiveness of Corticosteroid Nasal Spray vs Surgical Therapy in Patients With Severe to Extreme Anatomical Nasal Obstruction.
Teti VP; Akdagli S; Most SP
JAMA Facial Plast Surg; 2016 May; 18(3):165-70. PubMed ID: 26747790
[TBL] [Abstract][Full Text] [Related]
13. What is the value for money of medicines? A registry study.
Simoens S
J Clin Pharm Ther; 2012 Apr; 37(2):182-6. PubMed ID: 21812796
[TBL] [Abstract][Full Text] [Related]
14. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability.
Barbieri M; Drummond M; Willke R; Chancellor J; Jolain B; Towse A
Value Health; 2005; 8(1):10-23. PubMed ID: 15841890
[TBL] [Abstract][Full Text] [Related]
15. Representing uncertainty: the role of cost-effectiveness acceptability curves.
Fenwick E; Claxton K; Sculpher M
Health Econ; 2001 Dec; 10(8):779-87. PubMed ID: 11747057
[TBL] [Abstract][Full Text] [Related]
16. Early benefit assessment for pharmaceuticals in Germany: lessons for policymakers.
Schlette S; Hess R
Issue Brief (Commonw Fund); 2013 Oct; 29():1-9. PubMed ID: 24171232
[TBL] [Abstract][Full Text] [Related]
17. 'Health Economics' and the evolution of economic evaluation of health technologies.
Hutton J
Health Econ; 2012 Jan; 21(1):13-8. PubMed ID: 22147623
[No Abstract] [Full Text] [Related]
18. Is there an alternative to quality-adjusted life years for supporting healthcare decision making?
Beresniak A; Dupont D
Expert Rev Pharmacoecon Outcomes Res; 2016 Jun; 16(3):351-7. PubMed ID: 27139424
[TBL] [Abstract][Full Text] [Related]
19. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
[TBL] [Abstract][Full Text] [Related]
20. Costs of paying higher prices for equivalent effects on the Pharmaceutical Benefits Scheme.
Karnon J; Edney L; Sorich M
Aust Health Rev; 2017 Mar; 41(1):1-6. PubMed ID: 26954612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
